期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
In Vivo Animal Model Evaluation of a Powerful Oral Nanomedicine for Treating Breast Cancer in BALB/c Mice Using 4T1 Cell Lines without Chemotherapy
1
作者 Zahra Fakhroueian Alireza Massiha +5 位作者 Pegah Esmaeilzadeh Mehdi Assmar Afshin Zahedi Pouriya Esmaeilzadeh Sara Rezaei Shahab Rabiei Lalehdasht 《Advances in Nanoparticles》 CAS 2022年第3期73-109,共37页
Nanopharmaceuticals containing quantum dot nanoparticles (Q-Dot NPs) for treating serious cancers such as breast cancer have made fantastic proposals. In this study, ZnO quantum dot NPs are formulated via ZnO@PVP nano... Nanopharmaceuticals containing quantum dot nanoparticles (Q-Dot NPs) for treating serious cancers such as breast cancer have made fantastic proposals. In this study, ZnO quantum dot NPs are formulated via ZnO@PVP nanopolymer as co-assistants coordinating with efficacious suitable wetting agents, PEG-binding compound, and W/O emulsifier for producing eco-friendly water-based nanodrug. Several characterization techniques containing SEM, TEM, FTIR, photoluminescence, zeta potential, and UV-Vis absorption were employed for ZnO Q-Dot NPs in nanodrug. This work aims to investigate the anti-tumor effects of such nanomedicine on the 4T1 breast cancer cell line in BALB/c mice, being elaborated through intraperitoneal, injection (IVP) and oral therapy. The impressive findings showed that ZnO nanodrug caused changes in blood factors, having the most effectiveness at 40 μg/ml concentration after two weeks of oral treatments. The significant increase in white blood cells (WBC) neutrophils and meaningful decreases in lymphocytes and especially cholesterol were powerful simultaneous impacts, successfully treating malignant breast cancer masses. In this significant animal model research for breast cancer, the sick mice recovered entirely and even had a safe space to mate. Histopathological results showed no evidence of breast tumor formation or metastasis in the group treated with nanodrug and their children. This nanomedicine has a therapeutic effect, and is ready to be applied for treating volunteer breast cancer patients. However, its prevention (inhibitory) effect can also be analyzed and added to current data in future studies. 展开更多
关键词 NANOMEDICINE Nanodrug ZnO Q-Dot nps In Vivo Breast Cancer BALB/c Mice 4T1 cell lines Metastasis Oral Treatment
下载PDF
EGCG经Wnt1-β-catenin通路抑制NP69-LMP1细胞的增殖
2
作者 陈波 张志伟 +4 位作者 刘重元 赵强 蒋凯苓 杨科 罗招阳 《现代生物医学进展》 CAS 2012年第36期7034-7039,共6页
目的:探讨表没食子儿茶素没食子酸酯(Epigallocatechin-3-gallate,EGCG)体外抑制潜伏性膜蛋白1转化鼻咽上皮细胞NP69(NP69-LMP1)增殖的机制。方法:采用MTT法检测EGCG抑制NP69-LMP1细胞增殖的IC50值;选用细胞生长曲线、软琼脂集落形成实... 目的:探讨表没食子儿茶素没食子酸酯(Epigallocatechin-3-gallate,EGCG)体外抑制潜伏性膜蛋白1转化鼻咽上皮细胞NP69(NP69-LMP1)增殖的机制。方法:采用MTT法检测EGCG抑制NP69-LMP1细胞增殖的IC50值;选用细胞生长曲线、软琼脂集落形成实验和平皿克隆形成实验观察EGCG抑制NP69-LMP1细胞增殖的作用;采用Western-blot检测Wnt1、β-catenin的表达及磷酸化。结果:EGCG抑制NP69-LMP1细胞增殖的IC50值为47.7mg.L-1;EGCG对NP69-LMP1细胞增殖的抑制作用呈浓度和时间依赖性(n=3,P<0.05)。EGCG呈浓度依赖性抑制Wnt1和β-catenin蛋白的表达,促进β-catenin蛋白的磷酸化。结论:EGCG通过降低Wnt1和β-catenin蛋白表达,增加β-catenin蛋白磷酸化水平,发挥对NP69-LMP1细胞增殖的抑制作用。 展开更多
关键词 EGCG np69-lmp1细胞 Wnt1蛋白 Β-CATENIN蛋白 细胞增殖
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部